

NEXT Life Sciences Announces Successful Plan A™ Delivery Device Clinical Trial in Australia

Results Demonstrate the Effectiveness of a Revolutionary Male Contraceptive Delivery System

LOS ANGELES, CA, UNITED STATES, April 3, 2025 /EINPresswire.com/ -- NEXT Life Sciences, the modern reproductive healthcare company pioneering Plan A™, a first-of-its-kind, long-lasting, and on-demand reversible male contraceptive in development, announces the successful completion of its clinical trial in Australia with a 100% success rate. This milestone follows a previous [clinical evaluation in Canada](#) in 2024 and further solidifies Plan A™ as a breakthrough in male contraception that is on track to be a viable option for men within a couple of years.

“

Contraception has been lacking innovation for decades; we at NEXT Life Sciences are excited to continue to bring Plan A™ closer to fruition.”

*Dr. Darlene Walley, CEO of
NEXT Life Sciences*


Plan A™ is designed to offer men the first non-hormonal, long-acting, and on-demand reversible birth control. This innovative contraceptive uses a proprietary hydrogel, Vasalgel®, designed to filter out sperm for up to 10 years, and can be quickly administered by a medical professional in a variety of settings—not just clinics or hospitals. The proprietary access method tested in this Australian trial would allow for a confirmation that the hydrogel can be held in place, while also being less invasive than traditional methods, such as syringes or needles. Doctors have now successfully used the new delivery method introduced by

Plan A™ in procedures involving 27 men.

“Contraception has been lacking innovation for decades; we at NEXT Life Sciences are excited to continue to bring Plan A™ closer to fruition so men and couples can select from a variety of birth control options that best suit their lifestyles,” said Dr. Darlene R. Walley, Chief Executive Officer

NEXT LIFE SCIENCES ANNOUNCES SUCCESSFUL DELIVERY DEVICE TRIAL

Australian Clinical Results Demonstrate
100% Success Rate for New Delivery Method



Australian Clinical Results Demonstrate 100% Success
Rate for New Delivery Method

of NEXT Life Sciences. "Our clinical trials in Canada and Australia validate our approach while bringing us closer to further clinical trials and market launch."

NEXT Life Sciences has also announced it is in the process of its [Series A raise](#) to complete clinical trials. This follows prior oversubscribed funding of \$10 million and the Male Contraceptive Initiative's reaffirmation of its commitment to Plan A™ with a renewed grant.

"Plan A™ has the potential to be a game-changer for men and couples as they traverse their lives and careers, giving them an on-demand reversible contraception option," said Founder and Executive Chairman [L.R. Fox](#). "This is one of the reproductive health innovations NEXT Life Sciences plans to bring to market to revolutionize a critical area of health."

For more information, visit <https://www.nextlifesciences.org/> and <https://www.planaformen.com/>.

About NEXT Life Sciences

NEXT Life Sciences, Inc. (NEXT) is modernizing reproductive healthcare with its flagship product, Plan A™, a non-hormonal, long-lasting, and reversible male contraceptive. NEXT's executive management team and board members have proven track records of leadership across early-stage research, product development, and global commercialization, having served in leadership roles at successful medical device and contraceptive companies that developed and launched products that achieved iconic status.

Disclaimer

All forward-looking statements are not guarantees of future performance, and undue reliance should not be placed on them. Statements within this document have not been evaluated by the Food and Drug Administration. Plan A™ is currently not approved by the FDA for commercial distribution.

NEXT Life Sciences

Plan A™ Male Birth Control

+1 209-870-6398

press@nextlifesciences.org

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

[Instagram](#)

[TikTok](#)

[Other](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/799925673>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors

try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.